cagrilintide: Clinical Trials

33 trials of cagrilintide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed, 7 recruiting, 5 active not recruiting, 1 not yet recruiting. 18 Phase 3, 12 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 318Completed 10, Active not recruiting 5, Recruiting 2, Not yet recruiting 1
Phase 112Completed 7, Recruiting 5
Phase 23Completed 3

Follow cagrilintide: new trials by email Literature Review of cagrilintide trials Research Report on cagrilintide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
CagriSema, Semaglutide, Cagrilintide - Hypertension, Obesity
Phase 3Not yet recruitingNovo Nordisk A/S14082026-11-112026-11-05
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Cagrilintide, Placebo cagrilintide, Placebo semaglutide - Overweight, Obesity
Phase 3RecruitingNovo Nordisk A/S2852026-08-042026-09-04
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Cagrilintide, Placebo (matched to Cagrilintide) - Obesity, Overweight
Phase 1RecruitingNovo Nordisk A/S1142026-05-292026-10-19
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
Cagrilintide, Placebo Cagrilintide - Overweight, Obesity
Phase 1RecruitingNovo Nordisk A/S1202026-04-302026-05-15
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Cagrilintide, Semaglutide, Placebo cagrilintide - Obesity
Phase 1RecruitingNovo Nordisk A/S1002026-04-102026-05-07
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
Glucose-dependent Insulinotropic Polypeptide (GIP), Cagrilintide, Placebo GIP - Overweight, Obese
Phase 1RecruitingNovo Nordisk A/S1002026-02-092026-04-13
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Cagrilintide, Semaglutide, Placebo cagrilintide - Overweight, Obesity
Phase 3RecruitingNovo Nordisk A/S4602026-01-082026-09-30
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Cagrilintide, Placebo - Obesity, Overweight
Phase 3Active not recruitingNovo Nordisk A/S3002025-11-052026-08-06
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Cagrilintide, Placebo (matched to Cagrilintide) - Overweight, Obesity
Phase 3Active not recruitingNovo Nordisk A/S3302025-11-052026-11-16
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Cagrilintide, Semaglutide, Placebo cagrilintide - Obesity
Phase 1RecruitingNovo Nordisk A/S1442025-06-122026-09-10
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Cagrilintide, Semaglutide, Placebo cagrilintide - Obesity
Phase 3Active not recruitingNovo Nordisk A/S4002025-02-102026-01-20
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Cagrilintide, Semaglutide, Tirzepatide - Diabetes Mellitus, Type 2
Phase 3CompletedNovo Nordisk A/S10232024-11-052026-10-19
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Cagrilintide, Semaglutide, Placebo - Obesity
Phase 3CompletedNovo Nordisk A/S3002024-06-242026-05-05
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
NNC0194-0499, Semaglutide, NNC0194-0499 placebo - Alcohol-related Liver Disease
Phase 2CompletedNovo Nordisk A/S2702024-05-202026-03-12
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
Semaglutide, Cagrilintide, Placebo semaglutide - Diabetes Mellitus, Type 2
Phase 1CompletedNovo Nordisk A/S1582024-05-062026-02-27
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Cagrilintide, Semaglutide, Placebo - Chronic Kidney Disease, Type 2 Diabetes
Phase 2CompletedNovo Nordisk A/S6262024-04-012026-09-24
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Cagrilintide, Semaglutide, Placebo - Type 2 Diabetes
Phase 3CompletedNovo Nordisk A/S2742024-03-262026-09-09
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Cagrilintide, Semaglutide, Placebo - Type 2 Diabetes
Phase 3CompletedNovo Nordisk A/S1892024-03-192026-09-30
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Cagrilintide, Semaglutide, Atorvastatin - Obesity
Phase 1CompletedNovo Nordisk A/S342024-02-272026-05-19
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
Cagrilintide, Semaglutide, Placebo - Obesity
Phase 1CompletedNovo Nordisk A/S622024-02-232026-01-08

Showing 20 of 33. Sign in to see all of them.

Conditions studied

Obesity (23)  ·  Overweight (12)  ·  Diabetes Mellitus, Type 2 (10)  ·  Cardiovascular Diseases (1)  ·  Hypertension (1)  ·  Renal Insufficiency, Chronic (1)

Sponsors

Novo Nordisk A/S (33)

Countries

United States (20)  ·  Canada (15)  ·  Germany (15)  ·  Poland (11)  ·  United Kingdom (11)  ·  Denmark (10)  ·  Argentina (9)  ·  Australia (9)  ·  Hungary (9)  ·  Japan (9)  ·  India (8)  ·  Italy (8)  ·  Spain (8)  ·  Serbia (7)  ·  Bulgaria (6)

Results publications

PMID 39279639, PMID 40544432, PMID 40544433, PMID 41328546, PMID 42009015, PMID 42228334, PMID 42251856, PMID 42251859, PMID 42251860, PMID 42838477

NIH funding

2023 (8), 2025 (3)